MC2 Therapeutics’ drug candidate for hidradenitis suppurativa has shown hints of efficacy potential in a Phase IIa trial, sparking plans for Phase IIb development with a primary endpoint that may be a higher bar than previous approvals.
The Danish biotech obtained exclusive global rights, except for mainland China, Hong Kong, Macau and Taiwan, to the oral heat shock protein 90 (HSP-90) inhibitor, dubbed MC2-32, from Regranion last month.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.